Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.

doi:10.1371/journal.pone.0239686

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.

PloS one - 1 Jan 2020

Carlson Alexander S, Acevedo Rigo I, Lim Daniel M, Gulati Roman, Gawne Agnes, Sokolova Alexandra O, Cheng Heather H, Nelson Peter S, Montgomery R Bruce, Yu Evan Y, Schweizer Michael T

Abstract excerpt

INTRODUCTION: A significant proportion of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor mutations in homologous recombination (HR) repair genes, with some of these mutations associating with increased tumor susceptibility to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapy. While mutations in some HR repair genes (e.g., BRCA1/2) have been associated with...

Topics

Aged
Antineoplastic Agents
Ataxia Telangiectasia Mutated Proteins
BRCA2 Protein
Cyclin-Dependent Kinases
Drug Resistance, Neoplasm
Fanconi Anemia Complementation Group N Protein
Humans
MRE11 Homologue Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Male

Middle Aged

Mutation

Neoplasm Metastasis

Poly(ADP-ribose) Polymerase Inhibitors

Progression-Free Survival

Prostatic Neoplasms, Castration-Resistant

Recombinational DNA Repair

Steroid Synthesis Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32997692
DOI: 10.1371/journal.pone.0239686
PMCID: PMC7526881

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.PMID 32997692Read ↗

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.Semantic proximity Read ↗

Impact of homologous recombination repair gene mutations on survival in metastatic prostate cancer: A real-world analysis from an observational database.Semantic proximity Read ↗

Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.Semantic proximity Read ↗

Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.Semantic proximity Read ↗

Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study.Semantic proximity Read ↗

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.Semantic proximity Read ↗

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.